StockTipsArenaBeta

BUY Aurobindo Pharma — Kshitija Salvi, Globe Capital Market

BUYAurobindo Pharma

byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))27 Jul 2026via CNBC Awaaz.

Entry₹1,566.9Inferred
Target₹1,620
Total upside +3.39% (call closed)
Stop lossNot given
Exit₹1,6205 Aug 2026, 2:35 pm
Target hit+3.39%0.00%upside left
Follow Kshitija Salvi for new calls(29% target hit, 21 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 2 active Swing calls on AUROPHARMASee 116 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 9:49 pm IST
6 supporting2 neutral2 opposing
Supports the BUY call (6)

Aurobindo Pharma shares rise 2.01% in today's trade

NewsGoogle News·4 Aug · today

(opens in new tab)

Aurobindo Pharma FY26 Results: Revenue up 2.2% to ₹111,717 Cr

NewsGoogle News·3 Aug · yesterday

(opens in new tab)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·29 Jul · 1w ago

Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs). This royalty-free agreement aims to expand

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)

Aurobindo Pharma is acquiring majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA, expanding its business.

BSE · Company Update·23 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 2w ago

(opens in new tab)

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (2)

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Pharma stocks decline; Aurobindo Pharma down over 4%

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.